Journal
MOLECULAR & CELLULAR PROTEOMICS
Volume 18, Issue 9, Pages 1836-1850Publisher
ELSEVIER
DOI: 10.1074/mcp.RA118.001221
Keywords
-
Categories
Funding
- Swedish Breast Cancer Association (BRO)
- Region Skane
- Swedish National Health Service (ALF)
- Mrs Berta Kamprad Foundation
- BioCARE
- Marcus and Marianne Wallenberg Foundation
- Swiss National Science Foundation [3100A0-688 107679]
- DOD OCRP [W81XWH-15-1-0089]
- American Cancer Society [RSG-13-083-01-TBG]
- Ovarian Cancer Research Fund Liz Tilberis award
- Burroughs-Wellcome Fund Career Award in the Biomedical Sciences [1005320.01]
- Oncosuisse grant
Ask authors/readers for more resources
Protein biomarkers for epithelial ovarian cancer are critical for the early detection of the cancer to improve patient prognosis and for the clinical management of the disease to monitor treatment response and to detect recurrences. Unfortunately, the discovery of protein biomarkers is hampered by the limited availability of reliable and sensitive assays needed for the reproducible quantification of proteins in complex biological matrices such as blood plasma. In recent years, targeted mass spectrometry, exemplified by selected reaction monitoring (SRM) has emerged as a method, capable of overcoming this limitation. Here, we present a comprehensive SRM-based strategy for developing plasma-based protein biomarkers for epithelial ovarian cancer and illustrate how the SRM platform, when combined with rigorous experimental design and statistical analysis, can result in detection of predictive analytes. Our biomarker development strategy first involved a discovery-driven proteomic effort to derive potential Nglycoprotein biomarker candidates for plasma-based detection of human ovarian cancer from a genetically engineered mouse model of endometrioid ovarian cancer, which accurately recapitulates the human disease. Next, 65 candidate markers selected from proteins of different abundance in the discovery dataset were reproducibly quantified with SRM assays across a large cohort of over 200 plasma samples from ovarian cancer patients and healthy controls. Finally, these measurements were used to derive a 5-protein signature for distinguishing individuals with epithelial ovarian cancer from healthy controls. The sensitivity of the candidate biomarker signature in combination with CA125 ELISA-based measurements currently used in clinic, exceeded that of CA125 ELISAbased measurements alone. The SRM-based strategy in this study is broadly applicable. It can be used in any study that requires accurate and reproducible quantification of selected proteins in a high-throughput and multiplexed fashion.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available